{"id":"https://openalex.org/W4389232103","doi":"https://doi.org/10.1182/blood-2023-190753","title":"The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade","display_name":"The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389232103","doi":"https://doi.org/10.1182/blood-2023-190753"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-190753","doi":"https://doi.org/10.1182/blood-2023-190753","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-190753","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063781871","display_name":"Matthew Genyeh Mei","orcid":"https://orcid.org/0000-0002-1109-6955","observed_orcids":["https://orcid.org/0000-0002-1109-6955"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew G. Mei","raw_affiliation_strings":["1City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100432064","display_name":"Lu Chen","orcid":"https://orcid.org/0000-0001-9708-341X","observed_orcids":["https://orcid.org/0000-0001-9708-341X"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lu Chen","raw_affiliation_strings":["2Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036031227","display_name":"Sandrine Puverel","orcid":"https://orcid.org/0000-0002-8667-5193","observed_orcids":["https://orcid.org/0000-0002-8667-5193"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandrine Puverel","raw_affiliation_strings":["3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082326885","display_name":"Lihua Elizabeth Budde","orcid":"https://orcid.org/0000-0003-1464-5494","observed_orcids":["https://orcid.org/0000-0003-1464-5494"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Elizabeth Budde","raw_affiliation_strings":["3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012169173","display_name":"Swetha Kambhampati","orcid":"https://orcid.org/0000-0002-4783-2643","observed_orcids":["https://orcid.org/0000-0002-4783-2643"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Swetha Kambhampati","raw_affiliation_strings":["3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086060011","display_name":"Shari Daniels","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shari Daniels","raw_affiliation_strings":["1City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114104656","display_name":"Bev Dunning","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bev Dunning","raw_affiliation_strings":["1City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093396734","display_name":"Melissa Banez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Banez","raw_affiliation_strings":["4Clinical Trials Office, City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Clinical Trials Office, City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074743570","display_name":"Larry W. Kwak","orcid":"https://orcid.org/0000-0002-1884-5349","observed_orcids":["https://orcid.org/0000-0002-1884-5349"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry W. Kwak","raw_affiliation_strings":["3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030788778","display_name":"Alex Francisco Herrera","orcid":"https://orcid.org/0000-0002-9665-7415","observed_orcids":["https://orcid.org/0000-0002-9665-7415"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alex F. Herrera","raw_affiliation_strings":["5City of Hope, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5City of Hope, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1301076528"],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"1697","last_page":"1697"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9359999895095825,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9359999895095825,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.054499998688697815,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.9259999990463257},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9729999899864197},{"id":"https://openalex.org/keywords/cc-486","display_name":"CC-486","score":0.9819999933242798},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.8640000224113464},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.777999997138977},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.6370000243186951},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.6349999904632568},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.8330000042915344},{"id":"https://openalex.org/keywords/t-cell-infiltration","display_name":"T cell infiltration","score":0.6259999871253967},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6140000224113464},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6600000262260437},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4790000021457672}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.858587384223938},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8127521276473999},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.7600663900375366},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5870622992515564},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5842854976654053},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4684258699417114},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.435374915599823},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4203988313674927},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4186488687992096},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.41576752066612244},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2778850197792053},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.22357764840126038},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.19808873534202576},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-190753","doi":"https://doi.org/10.1182/blood-2023-190753","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-190753","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.800000011920929,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388586239","https://openalex.org/W3021851930","https://openalex.org/W2914827752","https://openalex.org/W3007246459","https://openalex.org/W2791043965","https://openalex.org/W2904705343","https://openalex.org/W3042573404","https://openalex.org/W2671701005","https://openalex.org/W3157524275","https://openalex.org/W2955654676"],"abstract_inverted_index":{"Introduction:":[0],"PD1":[1,28],"blockade":[2,29],"is":[3,25,46,589],"highly":[4],"active":[5],"in":[6,42,77,119,159,190,206,232,254,421,580,597],"patients":[7,17,283,614],"(pts)":[8],"with":[9,50,121,130,284,331,483,562,569,587],"relapsed/refractory":[10],"(RR)":[11],"Hodgkin":[12],"lymphoma":[13],"(HL);":[14],"however,":[15],"most":[16,515],"ultimately":[18],"progress":[19],"on":[20,228,242,251,481],"therapy,":[21,497],"and":[22,71,74,110,114,144,156,204,231,273,321,345,377,394,408,444,476,508,536,552,565,591],"HL":[23,52,95,123,132],"that":[24,48,88],"refractory":[26,56,124,146,349,600],"to":[27,57,67,96,125,147,152,263,301,511,610,617],"remains":[30],"an":[31,116,484],"unmet":[32],"need.":[33],"Furthermore,":[34],"as":[35,79,81,166,170,279,352,454,463],"PD-1":[36,58,73,97,126,148,162,599],"directed":[37,59,98,185],"therapies":[38,372],"are":[39,419],"being":[40],"administered":[41,222],"earlier":[43],"lines,":[44],"it":[45],"anticipated":[47],"pts":[49,120,129,313,386,435,479,495],"RR":[51,122,131],"will":[53],"be":[54,259],"increasingly":[55],"therapies.":[60,99],"Hypomethylating":[61],"agents":[62,399],"(HMA)":[63],"have":[64,314],"been":[65,315,608],"shown":[66,420],"increase":[68],"T-cell":[69],"infiltration":[70],"upregulate":[72],"CTLA-4":[75],"expression":[76],"tumors,":[78],"well":[80],"suppress":[82],"myeloid-derived":[83],"suppressor":[84],"cells.":[85],"We":[86],"hypothesized":[87],"HMA":[89],"might":[90],"restore":[91],"the":[92,108,182,212,271,280,302,464,558,605,623],"sentivity":[93],"of":[94,112,142,181,270,282,308,335,354,364,370,385,427,478,488,622],"Therefore,":[100],"we":[101],"conducted":[102],"a":[103,191,200,207,285,332,355,581,593,598,619],"phase":[104,214],"I":[105],"study":[106,606],"evaluating":[107],"safety":[109],"efficacy":[111],"nivolumab":[113,157,245],"CC-486,":[115],"oral":[117,154],"HMA,":[118],"blockade.":[127],"Methods:Adult":[128],"who":[133],"had":[134,341,347,379,387,391,396,402,410,411,452,461],"progressed":[135],"after":[136],"at":[137,194,211,223,237,319,323,504,615],"least":[138],"1":[139,503,509,578],"prior":[140,371,380,412],"line":[141],"therapy":[143,149],"were":[145,150,188,268,294,329,523,544],"enrolled":[151,316],"receive":[153],"CC-486":[155,220,234,588],"IV":[158,248],"28-day":[160],"cycles.":[161,571],"refractoriness":[163],"was":[164,221,235,249,373,429,442,447,471,576],"defined":[165,278,351],"progressive":[167],"disease":[168,501],"(PD)":[169],"best":[171,456,465],"response,":[172],"or":[173,177,289,359],"PD":[174,462],"while":[175],"receiving":[176],"within":[178,361],"12":[179],"weeks":[180],"last":[183],"anti-PD-1":[184],"therapy.":[186],"Pts":[187],"treated":[189],"dose-finding":[192],"cohort":[193,210],"2":[195,215,264],"dose":[196,208,216],"levels":[197],"(DL)":[198],"using":[199,298],"Rolling":[201],"6":[202,374,494],"design":[203],"then":[205],"expansion":[209],"recommended":[213],"(RP2D).":[217,325],"In":[218],"DL1,":[219],"200":[224],"mg":[225,239,247],"PO":[226,240],"daily":[227,241],"days":[229,243],"1-7,":[230],"DL2":[233,324,616],"dosed":[236],"300":[238],"1-7;":[244],"480":[246],"given":[250],"day":[252],"8":[253],"both":[255,398],"DLs.":[256],"Treatment":[257],"could":[258],"continued":[260],"for":[261,437,500],"up":[262],"years.":[265],"Primary":[266],"endpoints":[267],"determination":[269],"RP2D":[272],"overall":[274],"response":[275,287,291,438,595],"rate":[276,446,596],"(ORR)":[277],"proportion":[281],"complete":[286,356],"(CR)":[288,358],"partial":[290],"(PR).":[292],"Responses":[293],"assessed":[295],"by":[296],"investigators":[297],"PET-CT":[299],"according":[300],"2014":[303],"Lugano":[304],"Classification.":[305],"Results:":[306],"As":[307],"July":[309],"7,":[310],"2023,":[311],"21":[312],"including":[317,498],"3":[318,362,550],"DL1":[320],"18":[322],"At":[326,602],"baseline,":[327],"57%":[328],"male":[330],"median":[333,368,425,468,486],"age":[334],"40":[336],"years":[337],"(range":[338,375,474],"25-71),":[339],"95%":[340],"stage":[342],"III-IV":[343],"disease,":[344,350],"71%":[346,477],"primary":[348],"lack":[353],"remission":[357],"relapse":[360],"months":[363,473,490],"frontline":[365],"treatment.":[366],"The":[367,424,467,514,572],"number":[369,426],"2-14),":[376],"90%":[378],"brentuximab":[381],"vedotin":[382],"(BV).":[383],"76%":[384],"received":[388,392,397],"pembrolizumab,":[389],"67%":[390],"nivolumab,":[393],"43%":[395],"previously.":[400],"52%":[401],"undergone":[403],"autologous":[404],"stem":[405,414],"cell":[406,415],"transplant":[407],"5%":[409],"allogeneic":[413],"transplant.":[416],"Baseline":[417],"characteristics":[418],"Table":[422],"1.":[423],"cycles":[428],"7":[430],"(range:":[431],"3-17).":[432],"Among":[433],"19":[434],"evaluable":[436],"(2":[439],"pending),":[440],"ORR":[441],"63%":[443],"CR":[445],"10%.":[448],"An":[449],"additional":[450],"32%":[451],"SD":[453],"their":[455],"response;":[457],"only":[458,573],"one":[459,546],"pt":[460],"response.":[466],"follow-up":[469],"time":[470],"9":[472],"2.8-16.3),":[475],"remain":[480],"treatment":[482],"estimated":[485],"PFS":[487],"11.3":[489],"(95%":[491],"CI:":[492],"7.1-N/A).":[493],"stopped":[496],"4":[499,555],"progression,":[502],"treating":[505],"physician's":[506],"discretion":[507],"due":[510],"patient":[512,547],"preference.":[513],"common":[516],"adverse":[517],"events":[518],"(AEs),":[519],"any":[520],"grade":[521,577],"(Gr),":[522],"nausea":[524],"(86%),":[525],"diarrhea":[526],"(71%),":[527],"vomiting":[528],"(48%),":[529],"headache":[530],"(33%),":[531],"fatigue":[532],"(29%),":[533],"neutropenia":[534],"(19%),":[535],"anemia":[537,551],"(19%).":[538],"Only":[539],"two":[540],"Gr":[541,549,554],"3+":[542],"AEs":[543],"recorded:":[545],"experienced":[548],"another":[553],"hypercalcemia.":[556],"Notably,":[557],"hypercalcemia":[559],"fully":[560],"resolved":[561],"supportive":[563],"care":[564],"did":[566],"not":[567],"recur":[568],"subsequent":[570],"immune-related":[574],"AE":[575],"hypophysitis":[579],"single":[582],"pt.":[583],"Conclusions:":[584],"Nivolumab":[585],"combined":[586],"tolerable":[590],"elicits":[592],"high":[594],"cohort.":[601],"this":[603],"time,":[604],"has":[607],"amended":[609],"enroll":[611],"10":[612],"more":[613],"provide":[618],"better":[620],"estimation":[621],"efficacy.":[624]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}